RT Journal Article
SR Electronic
T1 CitySEIRCast: An Agent-Based City Digital Twin for Pandemic Analysis and Simulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.22.23300481
DO 10.1101/2023.12.22.23300481
A1 Bilal, Shakir
A1 Zaatour, Wajdi
A1 Otano, Yilian Alonso
A1 Saha, Arindam
A1 Newcomb, Kenneth
A1 Soo, Kim
A1 Kim, Jun
A1 Groen, Derek
A1 Michael, Edwin
YR 2023
UL http://medrxiv.org/content/early/2023/12/26/2023.12.22.23300481.abstract
AB The COVID-19 pandemic has dramatically highlighted the importance of developing simulation systems for quickly characterizing and providing spatio-temporal forecasts of infection spread dynamics that take specific accounts of the population and spatial heterogeneities that govern pathogen transmission in real-world communities. Developing such computational systems must also overcome the cold start problem related to the inevitable scarce early data and extant knowledge regarding a novel pathogen’s transmissibility and virulence, while addressing changing population behavior and policy options as a pandemic evolves. Here, we describe how we have coupled advances in the construction of digital or virtual models of real-world cities with an agile, modular, agent-based model of viral transmission and data from navigation and social media interactions, to overcome these challenges in order to provide a new simulation tool, CitySEIRCast, that can model viral spread at the sub-national level. Our data pipelines and workflows are designed purposefully to be flexible and scalable so that we can implement the system on hybrid cloud/cluster systems and be agile enough to address different population settings and indeed, diseases. Our simulation results demonstrate that CitySEIRCast can provide the timely high resolution spatio-temporal epidemic predictions required for supporting situational awareness of the state of a pandemic as well as for facilitating assessments of vulnerable sub-populations and locations and evaluations of the impacts of implemented interventions, inclusive of the effects of population behavioral response to fluctuations in case incidence. This work arose in response to requests from county agencies to support their work on COVID-19 monitoring, risk assessment, and planning, and using the described workflows, we were able to provide uninterrupted bi-weekly simulations to guide their efforts for over a year from late 2021 to 2023. We discuss future work that can significantly improve the scalability and real-time application of this digital city-based epidemic modelling system, such that validated predictions and forecasts of the paths that may followed by a contagion both over time and space can be used to anticipate the spread dynamics, risky groups and regions, and options for responding effectively to a complex epidemic.INDEX TERMS Agent-based Modeling, city-scale digital twins, disease transmission, epidemiology, geospatial modeling, healthcare interventions, lockdowns, microsimulation, model validation, synthetic populations, risk groups, vaccinations, visual analytics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by Hillsborough County, Florida, under Grant BOCC No: 22-0680.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PolicyMapI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors